Andrew Armstrong

@AarmstrongDuke

Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute, Durham NC

Chapel Hill, NC

Joined October 2016

170Following

2KFollowers

Andrew Armstrong@AarmstrongDuke · Jul 14

Choosing an ARPI in the mHSPC setting is a highly individualized decision. Our recent MAIC analysis compares ARCHES and ARANOTE similar cohorts for efficacy of enza vs daro for improving rPFS. Interesting results! tandfonline.com/doi/full/10.10… @DukeGUCancer @AzadOncology @DukeCancer

AarmstrongDuke's tweet card. To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using a ma...

763

Andrew Armstrong@AarmstrongDuke · Jul 12

Immune checkpoint blockade in MMRD mCRPC is effective! With some caveats… See our multicenter study results out today! @EurUrolOncol @DukeCancer @DukeGUCancer @NivenMehra @EmmanuelAntona1 sciencedirect.com/science/articl…

570

Andrew Armstrong Retweeted

Neeraj Agarwal, MD, FASCO@neerajaiims · Jul 10

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to @SFreedlandMD @nealshore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 @OncoAlert @urotoday @PCFnews

148

14.0K

Andrew Armstrong Retweeted

ArteraAI@arteraAI · Jul 10

We’re proud to share that the @US_FDA has granted Breakthrough Device Designation to ArteraAI Prostate—the first and only AI-powered risk stratification tool for prostate cancer to receive this status. A step forward for personalized, risk-based care: mpo-mag.com/breaking-news/…

392

Andrew Armstrong Retweeted

VJ Oncology@VJOncology · Jun 12

🎥@AarmstrongDuke of @DukeCancer shares 5-year OS ARCHES data: enzalutamide + ADT delivers sustained survival benefits in mHSPC across disease volumes—confirming durable long-term efficacy. 📺ow.ly/UswS50W4W9c @ASCO #ASCO25 #PCSM #TrialUpdate #CTSM #UroOnc #UroSoMe

464

Andrew Armstrong Retweeted

Neeraj Agarwal, MD, FASCO@neerajaiims · Jun 3

Congrats @AarmstrongDuke for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC #prostatecancer with enzalutamide @ASCO #ASCO25 👉66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide👇@OncoAlert @urotoday @PCF_Science @AzadOncology

5.0K

Andrew Armstrong@AarmstrongDuke · Jun 3

Thank you! #MedIQASCO25 and #ASCO25 for their support and @pfizer and @AstellasUS and @DukeGUCancer for so much support in these meaningful results!

SStephen Freedland, MD@SFreedlandMD · Jun 3

Updated results from #ARCHES in mHSPC showing sustained benefits of #enzalutamide with minimum 5 year followup. 3 year survival benefit in high volume disease! Amazing results! @AarmstrongDuke @AzadOncology #ASCO25

651

Andrew Armstrong@AarmstrongDuke · Jun 3

Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

AarmstrongDuke's tweet image. Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

3.0K

Andrew Armstrong@AarmstrongDuke · Jun 3

Digital pathology and clinical multimodal AI again can predict treatment needs in prostate cancer, now with abiraterone in STAMPEDE at #ASCO25 #MedIQASCO25 @arteraAI in very high risk disease! Predictive and prognostic for MFS, PCSM.

AarmstrongDuke's tweet image. Digital pathology and clinical multimodal AI again can predict treatment needs in prostate cancer, now with abiraterone in STAMPEDE at #ASCO25 #MedIQASCO25 @arteraAI in very high risk disease! Predictive and prognostic for MFS, PCSM.

1.0K

Andrew Armstrong@AarmstrongDuke · Jun 3

CAN-2409 is the first oncolytic and immunogenicity virus to delay progression in intermediate risk prostate cancer! Great work from @JohnsHopkins Ted DeWeese at #ASCO25 #MedIQASCO25. N=744 HR for DFS 0.52 p=.0155

AarmstrongDuke's tweet image. CAN-2409 is the first oncolytic and immunogenicity virus to delay progression in intermediate risk prostate cancer! Great work from @JohnsHopkins Ted DeWeese at #ASCO25 #MedIQASCO25. N=744 HR for DFS 0.52 p=.0155

526

Andrew Armstrong@AarmstrongDuke · Jun 2

Terbium-PSMA RLT has activity and safety in mCRPC, very similar to Lu177! Need more comparative data but nice to see alternative beta emitters and first Auger emitter in patients! #MedIQASCO25 #ASCO25 @PeterMacCC PSA50 of 70%, rPFS 11 mo, well tolerated.

AarmstrongDuke's tweet image. Terbium-PSMA RLT has activity and safety in mCRPC, very similar to Lu177! Need more comparative data but nice to see alternative beta emitters and first Auger emitter in patients! #MedIQASCO25 #ASCO25 @PeterMacCC PSA50 of 70%, rPFS 11 mo, well tolerated.

293

Andrew Armstrong@AarmstrongDuke · Jun 2

Bullseye trial shows delays in progression in PET mHSPC without ADT. But short lived…#ASCO25 #MedIQASCO25. Is this better than MDT?

AarmstrongDuke's tweet image. Bullseye trial shows delays in progression in PET mHSPC without ADT. But short lived…#ASCO25 #MedIQASCO25. Is this better than MDT?

8.0K

Andrew Armstrong@AarmstrongDuke · Jun 2

Highlighting this @ThePCCTC and @DukeGUCancer trial of a novel CTLA engaging IO plus Lu177-PSA-617 therapy in men with mCRPC at #ASCO25 #MedIQASCO25 with @TiansterZhang . Clear activity and safe!

AarmstrongDuke's tweet image. Highlighting this @ThePCCTC and @DukeGUCancer trial of a novel CTLA engaging IO plus Lu177-PSA-617 therapy in men with mCRPC at #ASCO25 #MedIQASCO25 with @TiansterZhang . Clear activity and safe!

3.0K

Andrew Armstrong Retweeted

Dan George@Daniel_J_George · Jun 2

Sneak preview of @AarmstrongDuke presenting ARCHES 5-year OS data of ENZA + ADT in pts with mHSPC on Tuesday 9:45 am Oral session, Hall D1. Probability of being alive 66%, so 2/3 of pts still alive after 5 years. 115k pts in global study. @Dukecancer @DukeGUCancer

5.0K

Andrew Armstrong@AarmstrongDuke · Jun 1

Pasritamig is active! And hk2 is a selective target in prostate cancer. #ASCO25 abstract 5017 shows this new BiTE has an ORR of 8% with 43% PSA50 and rPFS 7.9 mo with CRS in <10%. #MedIQASCO25 worth further study @ThePCCTC @JNJNews see ascopubs.org/doi/abs/10.120…

651

Andrew Armstrong@AarmstrongDuke · Jun 1

Interesting EVOLUTION for immunoradioligand combination of ipi/nivo in mCRPC: greater responses and rPFS vs Lu177-PSMA-617 alone @PeterMacCC at #ASCO25 #MedIQASCO25 but more cardiac toxicity. Need better IOs in prostate cancer!

AarmstrongDuke's tweet image. Interesting EVOLUTION for immunoradioligand combination of ipi/nivo in mCRPC: greater responses and rPFS vs Lu177-PSMA-617 alone @PeterMacCC at #ASCO25 #MedIQASCO25 but more cardiac toxicity. Need better IOs in prostate cancer!

464

Andrew Armstrong@AarmstrongDuke · Jun 1

Targeting B7-H3 in post ARPI refractory mCRPC pays off with a new ADC: DB-1311/BNT324. ORR of 42% and 6 mo PFS rate of 68% warrants future controlled trials! Abstract 5015 at #ASCO25 #MedIQASCO25 @ThePCCTC

$AarmstrongDuke's tweet image. Targeting B7-H3 in post ARPI refractory mCRPC pays off with a new ADC: DB-1311/BNT324. ORR of 42% and 6 mo PFS rate of 68% warrants future controlled trials! Abstract 5015 at #ASCO25 #MedIQASCO25 @ThePCCTC$

689

Andrew Armstrong Retweeted

Edmond Kwan@EdmondMKwan · May 27

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across…

103

8.0K

Andrew Armstrong@AarmstrongDuke · May 27

Enjoyed this NPR discussion on prostate cancer with @WFAE’s Mike Collins and @unchealth urologist Kathryn Hacker Gessner. wfae.org/show/charlotte… @DukeGUCancer @DukeCancer

AarmstrongDuke's tweet card. On the next Charlotte Talks, we look at the treatment, screening and testing options for prostate cancer patients. We also look at promising new treatment research recently released by Duke Univers...

240

Andrew Armstrong@AarmstrongDuke · May 23

This is a great story of one of my ARCHES patients on @WRAL highlighting our data coming out at #ASCO25. Need to watch on your computer: wral.com/lifestyle/heal… @DukeGUCancer @AstellasUS @DukeCancer @AzadOncology

AarmstrongDuke's tweet card. Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research...

291